Dr. Eric Goosby has been CEO and Chief Medical Officer of Pangaea Global AIDS Foundation since 2001. In this capacity, Dr. Goosby has played an important role in the development and/or implementation of HIV/AIDS national treatment scale-up plans in Rwanda, South Africa, China, and Ukraine.

He has extensive international experience in the development of treatment guidelines for use of antiretroviral therapies, clinical mentoring and training of health professionals, and the design and implementation of local models of care for HIV/AIDS. Dr. Goosby focuses his expertise on the scale-up of sustainable HIV/AIDS treatment capacity, including the delivery of HIV antiretroviral drugs, within existing healthcare systems.

A native son of San Francisco, Dr. Goosby was treating patients at San Francisco General Hospital when AIDS first began to take its devastating toll on the City. In 1986, he became AIDS activity division attending physician, and the following year was appointed associate medical director of SF General’s AIDS Clinic. During his tenure, he conceived of a new strategies for the entry and retention of HIV-infected intravenous drug users into HIV clinical care, establishing three medical facilities located in methadone treatment centers. He was also the principal investigator for numerous AIDS Clinical Trial Group Studies.

In 1991, Dr. Goosby moved to a position in the federal government as director of HIV Services at the U.S. Public Health Service/Health Resources and Services Administration. In this position, he administered the Ryan White CARE Act, overseeing the distribution of federal funds and the planning of services in 25 AIDS epicenters and all States in the United States and its territories.

In 1994, Dr. Goosby became director of the Office of HIV/AIDS Policy in the Department of Health and Human Services. In this position, he was a strong advocate for responsible government policy in the areas of HIV/AIDS prevention, treatment and research, advised on the federal HIV/AIDS budget, and worked with Congress on all AIDS-related issues.
In 1995, Dr. Goosby saw the need for explicitly defining how to use a new class of drugs, protease inhibitors, to allow for rapid incorporation of these drugs into treatment plans for both infectious disease specialists and more importantly, general practitioners caring for HIV patients. He created and convened the DHHS Panel on Clinical Practices for the Treatment of HIV Infections. This committee defined how to use protease inhibitors in conjunction with already existing antiretrovirals.

The committee later expanded its works to address standards of care for antiretroviral use for pediatric patients and pregnant women. Dr. Goosby has remained actively involved in this Panel, now known the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, which is widely recognized as defining the standard of care for HIV/AIDS treatment in the United States.

In 1997, while still in his position at HHS, Dr. Goosby also acted as interim director of the National AIDS Policy Office at the White House, reporting directly to the President as his senior advisor on HIV-related issues. In 1998 he helped to foster and orchestrate the dialogue on racial disparities in HIV/AIDS that led to the Minority AIDS Initiative. Dr. Goosby’s office was responsible for guiding the implementation of the Initiative at HHS over the next three years. Dr. Goosby’s office also coordinated scientific reviews of needle exchange as a public health intervention.

In 2000, while working as the director of HIV/AIDS policy at the Department of Health and Human Services, he served as acting deputy director of the National AIDS Policy Office in the White House. In these roles, Dr. Goosby had continuing involvement in the Ryan White CARE Act and its reauthorization, and participated in the definition and creation of a coordinated response to HIV/AIDS in the global setting, which became the LIFE initiative during the Clinton Administration.